Top investor Rakesh Jhunjhunwala says steering away from Indian IPOs
Rakesh Jhunjhunwala says he is steering clear of all IPOs for now as valuations have skyrocketed amid strong inflows and exuberance in equity markets
Mumbai: Major Indian share investor Rakesh Jhunjhunwala said he is steering clear of all initial public offerings (IPOs) for now as valuations have skyrocketed amid strong inflows and exuberance in equity markets.
India has had a boom in IPOs, with a record $11 billion raised this year. However, high valuations—especially for some recent insurance IPOs—have produced some weak secondary market debuts and weighed on investor sentiment in recent weeks.
“There is a lot of froth in the IPO market,” Jhunjhunwala, a billionaire who runs his own asset management firm, said at the Reuters Global Investment 2018 Outlook Summit. “Stay away.”
Jhunjhunwala, often dubbed by Indian media as the country’s Warren Buffett, added that he has largely avoided the recent spate of IPOs and has unwound the few small bets he placed in these offerings.
He said that the recent tepid listings could lead to a “lull” in the IPO pipeline, and companies coming to market might readjust their pricing. “They will have to wait for two to three months and then come at lower or fairer valuations,” the investor said.
According to Forbes, Jhunjhunwala has a net worth of about $2.9 billion. He made his fortune from equity investments, and his stock picks are closely watched by India’s retail and institutional investors.
India’s share markets have logged a string of record highs, despite an elusive earnings recovery and confusion stemming from the 1 July roll-out of a major tax reform. This has stretched valuations in several sectors, raising concerns of a potential correction.
Jhunjhunwala said he expects a rebound in corporate earnings in the remainder of the current fiscal year, which ends in March, with early signs already evident in the quarter ended 30 September. The market veteran said he also expects a weakening rupee in 2018 to act as a tailwind for export-oriented Indian drugmakers, making stocks in that sector more attractive.
Regulatory scrutiny and pricing pressure on medicines in the US in the last couple of years have dented profits at Indian drugmakers, which supply roughly a third of the generic medicines sold there. The Nifty Pharma Index has fallen some 34% from its record high in April 2015. In contrast, the main market index has gained nearly 18% in that period.
Jhunjhunwala said he sees some of the current pressure on the price of drugs coming off shortly, adding “If you take a long term view of 4-5 years, there could be opportunities in a lot of pharma stocks.”
On overall equity markets, Jhunjhunwala cautioned that given the sustained rally since the beginning of 2016, there may be a correction in the near-term, but he does not expect the bullish trend to end anytime soon.
“Markets may in the short-term correct. But in a bull market the correction is always sharp, swift and short-lived,” Jhunjhunwala said. Reuters